https://transhumanist.ru/index.php?action=history&feed=atom&title=NMUR1 2026-04-19T12:14:12Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=NMUR1&diff=4134&oldid=prev 2021-04-29T19:02:28Z

<p>Новая страница: «Neuromedin-U receptor 1 (NMU-R1) (G-protein coupled receptor 66) (G-protein coupled receptor FM-3) [GPR66] ==Publications== {{medline-entry |title=[Medicinal Ch...»</p> <p><b>Новая страница</b></p><div>Neuromedin-U receptor 1 (NMU-R1) (G-protein coupled receptor 66) (G-protein coupled receptor FM-3) [GPR66]<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=[Medicinal Chemistry Focused on Mid-sized Peptides Derived from Biomolecules].<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31685733<br /> |abstract=Biomolecule-derived peptides are attractive research resources to develop drugs and elucidate the basic mechanisms of life phenomena. This review article focuses on two biomolecules called &quot;neuromedin U ([[NMU]])&quot; and &quot;myostatin&quot; that are deeply involved in obesity and muscle weakness caused by modern lifestyles and aging. A structure-activity relationship (SAR) study based on a biomolecule reveals the structural features required for the biological activity and gives clues leading the drug discovery process. [[NMU]] activates two types of receptors ([[[[NMU]]R1]] and [[NMU]]R2). [[NMU]], which is an attractive candidate for treating obesity, displays a variety of physiological actions in addition to appetite suppression. The discovery of useful receptor-selective agonists helps in elucidating the detailed roles of the respective receptors for each action and in developing therapeutic drugs based on receptor function. Hence, SAR studies focused on the amidated C-terminal heptapeptide of [[NMU]] were carried out to obtain selective agonists. Consequently, the respective hexapeptidic [[[[NMU]]R1]] and [[NMU]]R2 agonists CPN-267 and CPN-116 were discovered. Myostatin, an endogenous negative regulator of skeletal muscle mass, is a promising target for treating muscle atrophy disorders. Focused on the inactivation mechanism of mature myostatin by the myostatin precursor-derived prodomain, a core peptide (23-mer) for effective myostatin inhibition was identified from the mouse myostatin prodomain sequence. The SAR study based on this core peptide afforded a 25-fold more potent derivative (16-mer), which increased skeletal muscle mass and hindlimb grip strength. Therefore, this derivative could be a novel platform for a peptidic drug useful in the treatment of muscle atrophy.<br /> |mesh-terms=* Aging<br /> * Chemistry, Pharmaceutical<br /> * Drug Discovery<br /> * Humans<br /> * Life Style<br /> * Molecular Targeted Therapy<br /> * Muscle Weakness<br /> * Muscular Atrophy<br /> * Myostatin<br /> * Neuropeptides<br /> * Obesity<br /> * Peptides<br /> * Receptors, Neurotransmitter<br /> * Structure-Activity Relationship<br /> |keywords=* myostatin inhibitor<br /> * neuromedin U receptor-selective agonist<br /> * peptide<br /> |full-text-url=https://sci-hub.do/10.1248/yakushi.19-00149<br /> }}</div>

OdysseusBot